Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age5-60
SponsorSouth Valley University

About this trial

Mycobacterium leprae is a slow-growing bacillus that causes leprosy. the infection may take two to ten years to incubate. While the exact mechanism of infection transmission is unknown, direct bacillus absorption through the nasal or respiratory mucosa and aerosolized nasal secretions are the most common theories. The bacteria is subsequently transported by the bloodstream to the peripheral nerves, where it can result in tissue damage from painless burns and ulcers as well as irreparable nerve damage that results in a loss of protective feeling.

Eligibility criteria

Qualifiers

Patients of both sexes with positive slit skin smear for m.leprae .

Disqualifiers

Patients with hypersensitivity to sulfa .

Patients with hypersensitivity to clofazimine or rifampcin.

pregnant or lactating women.

Trial design

Treatments tested in this trial

  • Dapsone

Treatment groups

50 Participants
are divided into 2 treatment groups

Sponsors and collaborators